Abstract:Abstract Background Inflammatory bowel disease (IBD) patients may experience a suboptimal response to anti-tumour necrosis factor (TNF) therapy. In China, these data are limited. The EXPLORE study aimed to assess the incidence and indicators of suboptimal response to first-line anti-TNF agents in IBD patients in real-world practice in the newly industrialised countries. Methods The EXPLORE study was a multinational, retrospective chart review study. In the China subgroup, adult patients from 10 centres diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) and who initiated first anti-TNF treatment between March 2010 and March 2015, were included. The cumulative incidence (CI) of suboptimal response was assessed over 24 months since the anti-TNF initiation. The indicators of suboptimal response included: IBD-related hospitalisation, dose-escalation, discontinuation including switch to another anti-TNF, non-biologic therapy augmentation, or IBD-related surgery. Primary non-response (PNR) and secondary loss of response (SLOR) were defined as any suboptimal response indicator at <4 and ≥4 months after anti-TNF initiation, respectively. Results Overall, 287 first-line anti-TNF treated patients (35 UC; 252 CD) were included: male, UC 54.3% (n = 19), CD 74.6% (n = 188); mean (SD) age (years), UC 43.1 (14.2), CD 31.9 (11.3); median (min-max) disease duration (years), UC 1.0 (0–9), CD <1 year (0–21); median (min-max) follow-up (months), UC 27.6 (24–60), CD 40.0 (24–60). At 12 and 24 months, the CI of suboptimal response to first anti-TNF treatment was 51.4% and 75.7% in UC, 45.4% and 57.0% in CD, respectively (Figure 1). The median time to the first suboptimal response was 7.2 months in UC and 14.3 months in CD. The CI of PNR was 31.2% in UC and 33.7% in CD. The CI of SLOR was 29.4% and 64.7% in UC, 17.7% and 35.2% in CD at 12 and 24 months, respectively. The most frequent first suboptimal response indicator was ‘discontinuation of anti-TNF therapy’ in UC patients (56.3%) while for CD patients it was ‘IBD-related hospitalisation’ (56.1%) followed by ‘augmentation with non-biological therapy’ in both cohorts (UC 31.3%; CD 22.8%). Conclusion Approximately three-quarters of UC and over half of CD patients experienced a suboptimal response to their first anti-TNF agent at 24 months. Given the high unmet needs observed with anti-TNF therapies in China, IBD patients may benefit from greater optimisation of care and new biologic options.

Optimal Therapy of Biologics in Crohn′s Disease

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

Optimizing Biologic Treatment in IBD: Objective Measures, but When, How and How Often?

Optimal timeframe for achieving biochemical remission in Crohn's disease patients treated with first-line biologics: A retrospective multicenter study

Optimizing Effect of Infliximab Upon Inflammatory Bowel Disease

Biologic Therapy of Crohn’s Disease: Infliximab

Biologics for the treatment of inflammatory bowel disease in adults: options and switches

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

Patients Selection for Top-Down Treatment in Ulcerative Colitis

Biologic dual target therapy for refractory Crohn′s disease: five cases and literature review

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

Efficacy of Biological Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: a Protocol for a Systematic Review and an Individual-Patient Level Meta-Analysis of Randomised Controlled Trials

Clinical Treatment Strategy of Crohn' s Disease

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND INDVIDUAL-PATIENT-DATA METANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies

Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology

Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis